Agios Pharmaceuticals, Inc. (AGIO) Wednesday said the Food and Drug Administration or FDA has granted orphan drug designation to the company's drug candidate tebapivat for the treatment of myelodysplastic syndromes (MDS), a group of blood cancers.
A Phase 2a study of tebapivat in lower-risk MDS was completed last year. Agios is currently initiating a Phase 2b study of tebapivat in lower-risk MDS.
Orphan drug designation provides various benefits including tax credits, exemptions from certain FDA fees for clinical trials, and eligibility for seven years of market exclusivity after the drug is approved.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.